Diagnosis/Pathophysiology of Glucocorticoid Remediable Aldosteronism Hypertension
NCT00005394 · Status: COMPLETED · Type: OBSERVATIONAL
Last updated 2016-05-13
Summary
To identify and study a large cohort of glucocorticoid remediable aldosteronism (GRA) patients.
Conditions
- Cardiovascular Diseases
- Hypertension
- Heart Diseases
Sponsors & Collaborators
-
National Heart, Lung, and Blood Institute (NHLBI)
lead NIH
Principal Investigators
-
Richard Lifton · Yale University
Eligibility
- Max Age
- 100 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 1995-08-31
- Completion
- 2000-07-31
More Related Trials
-
Predicting Reduction of Hypertension After Adrenalectomy for Primary Aldosteronism: a Multicenter Analysis
NCT04761354 ·Status: COMPLETED
-
The Role of Mineralocorticoid Receptors in Vascular Function
NCT00759525 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Cardiovascular Manifestations of MR Activation in Primary Aldosteronism: Pilot Clinical Study
NCT05030545 ·Status: RECRUITING ·Phase: PHASE4
-
Importance of Aldosterone in the Pathogenesis of Hypertensive Heart Disease
NCT00865501 ·Status: COMPLETED ·Phase: PHASE3
-
Effect of Renin Angiotensin Aldosterone System Genetic Polymorphism on the Pharmacological Effect of Mineralocorticoid Receptor Antagonists in Patients With Myocardial Infarction
NCT05873400 ·Status: UNKNOWN
-
Prospective Phenotyping of Autonomous Aldosterone Secretion
NCT03484130 ·Status: ACTIVE_NOT_RECRUITING
-
Impacts of Aldosterone Blockade on Myocardial Remodeling in Hypertensive Patients With Diastolic Failing Heart
NCT01944384 ·Status: COMPLETED ·Phase: PHASE4
-
Cardiovascular Evaluation of Adult PHA 1 Patients
NCT00646828 ·Status: COMPLETED
-
REnin-guided TherApy With MinEralocorticoid Receptor Antagonists in Primary Aldosteronism - Feasibility Study
NCT06108427 ·Status: RECRUITING ·Phase: NA
-
Identification of Patient Phenotypes Associated With Elevated Aldosterone Levels
NCT01614860 ·Status: COMPLETED
-
Effect of MRA on Cardiovascular Disease in Patients With Hypertension and Hyperaldosteronemia
NCT05688579 ·Status: ENROLLING_BY_INVITATION ·Phase: PHASE4
-
Primary Aldosteronism in General Practice: Organ Damage, Epidemiology and Treatment
NCT01728493 ·Status: COMPLETED
-
Mineralocorticoid Antagonism and Endothelial Dysfunction in Autosomal Dominant Polycystic Kidney Disease (ADPKD)
NCT01853553 ·Status: COMPLETED ·Phase: PHASE3
-
Aldosterone and Vascular Disease in Diabetes Mellitus
NCT00214825 ·Status: COMPLETED ·Phase: NA
-
Search of Biomarkers of Mineralocorticoid Receiver Activity : the Value of Neutrophil Gelatinase Associated Lipocalin (NGAL)in Serum or Urine in Human
NCT02129621 ·Status: COMPLETED ·Phase: NA
-
The Effect of Spironolactone on Acute Kidney Injury in Patients Undergoing Coronary Angiography
NCT03329443 ·Status: COMPLETED ·Phase: PHASE2
-
Diuretics, Hypertension, and Arrhythmias Clinical Trial
NCT00000525 ·Status: COMPLETED ·Phase: PHASE3
-
Autoregulation of Glomerular Filtration Rate in Patients With Type 1 Diabetes During Spironolactone Therapy
NCT00335413 ·Status: COMPLETED ·Phase: PHASE4
-
The Diagnostic Performance of 24-hour Urinary Aldosterone for Primary Aldosteronism
NCT06236698 ·Status: COMPLETED
-
Is the Evolution of the Aldosterone-renin Ratio Pre- Versus Post-operative on Day 1 Following Unilateral Adrenalectomy for Primary Hyperaldosteronism Predictive of Blood Pressure Outcomes
NCT07110155 ·Status: NOT_YET_RECRUITING
-
Postoperative Cardiovascular Index Change of Primary Aldosteronism
NCT00746070 ·Status: UNKNOWN
-
Diagnosing and Targeting Mechanisms of Diuretic Resistance in Heart Failure
NCT02546583 ·Status: COMPLETED ·Phase: PHASE1
-
Effects of Adrenal Artery Ablation and Spironolactone in Patients With Primary Aldosteronism
NCT04409431 ·Status: RECRUITING ·Phase: NA
-
Primary Aldosteronism in Western Norway
NCT02832388 ·Status: RECRUITING
-
Diagnosing Variable Primary Aldosteronism.
NCT05765786 ·Status: RECRUITING